Neurotransmitter Or Derivative Affecting Or Utilizing Patents (Class 514/18.1)
-
Publication number: 20120134991Abstract: The present invention provides for prevention and/or treatment of neurological or neuropsychiatric disorders involving abnormal D1-D2 dopamine receptor coupling and/or activation. Methods and agents are provided for modulating dopamine receptor function arising from D1-D2 coupling and/or activation. Agents of the present invention include fragments of D2 receptor or D1 receptor that can disrupt D1-D2 coupling.Type: ApplicationFiled: June 12, 2009Publication date: May 31, 2012Applicant: CENTRE FOR ADDICTION AND MENTAL HEALTHInventor: Fang Liu
-
Publication number: 20120129783Abstract: The present invention is directed to a method of treating a patient suffering from the metabolic syndrome and/or related disorders including obesity, Type 2 diabetes, pre-diabetes, hypertension, dyslipidemia, insulin resistance, endothelial dysfunction, pro-inflammatory state, and pro-coagulative state, and comprising the steps of (a) providing to the patient a dietary regimen that decreases overactive CNS noradrenergic tone; followed by (b) providing to the patient a dietary regimen that increases dopaminergic tone while maintaining the above decreased overactive CNS noradrenergic tone. The present invention is also directed to food products useful in implementing the dietary regimens.Type: ApplicationFiled: September 19, 2011Publication date: May 24, 2012Inventor: Anthony Cincotta
-
Publication number: 20120115773Abstract: The method of the invention relates to a modified OmCI polypeptide or a polynucleotide encoding a modified OmCI polypeptide which lacks LK/E binding activity and the use of such polypeptides and polynucleotides for the treatment of a disease or condition mediated by complement.Type: ApplicationFiled: February 4, 2010Publication date: May 10, 2012Inventors: Miles A. NUNN, Susan M. Lea, Pietro Roversi
-
Publication number: 20120114703Abstract: Methods for treating conditions in an animal or human subject. The conditions may be pain, skeletal muscle conditions, smooth muscle conditions, glandular conditions and cosmetic conditions. The methods comprise the step of administering a Clostridium neurotoxin component or Clostridium neurotoxin component encoding DNA to the subject using a needleless syringe.Type: ApplicationFiled: August 18, 2011Publication date: May 10, 2012Applicant: ALLERGAN, INC.Inventor: Patricia S. Walker
-
Publication number: 20120115792Abstract: Infraorbital dark circles can be treated by administration of a botulinum toxin to a patient. The botulinum toxin can be botulinum toxin type A and the botulinum toxin can be administered to or to the vicinity of an eye of a patient with infraorbital dark circles.Type: ApplicationFiled: November 7, 2011Publication date: May 10, 2012Applicant: ALLERGAN, INC.Inventor: Christopher A. Dadas
-
Publication number: 20120101027Abstract: The present invention relates to treatment of disease by inhibition of cellular secretory processes, to agents and compositions therefor, and to manufacture of those agents and compositions. The present invention relates particularly, to treatment of disease dependent upon the exocytotic activity of endocrine cells, exocrine cells, inflammatory cells, cells of the immune system, cells of the cardiovascular system and bone cells.Type: ApplicationFiled: January 6, 2012Publication date: April 26, 2012Applicant: SYNTAXIN LIMITEDInventors: Keith Alan FOSTER, John Andrew CHADDOCK, Conrad Padraig QUINN, John Robert PURKISS
-
Publication number: 20120040886Abstract: The present invention relates to novel analogues of neuropeptide Y, pharmaceutical compositions containing the same, pharmaceutical formulations containing the same, and method of treating diseases or conditions mediated by neuropeptide Y-receptor binding. More particularly, the present invention relates to novel analogues of neuropeptide Y having proline substitution at position 34 and other substitution(s) as defined herein that selectively bind to the neuropeptide Y1 receptor subtype compared to the neuropeptide Y2 receptor subtype.Type: ApplicationFiled: February 19, 2010Publication date: February 16, 2012Inventor: Zheng Xin Dong
-
Publication number: 20120028906Abstract: A method for affecting the timing of cervical ripening and the resultant onset of parturition in a pregnant female mammal, the method comprises administering to a pregnant female one or more than one dose of an agent that chemically mimics innervation of the cervix by the vagus nerve, thereby advancing the onset of parturition, or administering to a pregnant female one or more than one dose of an agent that chemically blocks innervation of the cervix by the vagus nerve, thereby delaying the onset of parturition.Type: ApplicationFiled: March 10, 2010Publication date: February 2, 2012Applicant: LOMA LINDA UNIVERSITYInventor: Steven M. Yellon
-
Publication number: 20120004179Abstract: The present invention relates to an antibody which specifically binds to unprocessed and/or partially processed neurotoxin polypeptide or an antibody which specifically binds an epitope consisting of a peptide having an amino acid sequence as shown in any one of SEQ ID NOs: 1 to 16 and to methods for the manufacture of such antibodies. Moreover, the present invention relates to a composition comprising processed neurotoxin polypeptide free of unprocessed or partially processed neurotoxin polypeptide and a method for manufacturing said neurotoxin polypeptide based on the antibodies of the invention. The present invention also relates to the use of the aforementioned antibody for separating processed neurotoxin polypeptides from unprocessed or partially processed neurotoxin polypeptides or for determining unprocessed or partially processed neurotoxin polypeptides. The present invention relates to a method for the manufacture of a medicament.Type: ApplicationFiled: February 17, 2010Publication date: January 5, 2012Applicant: MERZ PHARMA GmbH & CO. KGaAInventors: Michael Pfeil, Josef Friedrich, Harold Victor Taylor, Karl-Heinz Eisele, Cornelia Brunn
-
Publication number: 20110318355Abstract: The present application concerns mutant proteins of the fusion protein (F protein) of the parainfluenza virus (PIV) which are currently indexed as type 5 PIV (PIV-5 or PIV5) and type 2 PIV (PIV-2 or PIV2). The present application concerns products deriving therefrom, such as: nucleic acids, vectors, cells, fusion inhibitors of the antibody, aptamer, interfering RNA type; myelomas, hybridomas; stem and progenitor cells. The present application also concerns mutant proteins and products derived therefrom for use in medical and biotechnological applications.Type: ApplicationFiled: November 17, 2009Publication date: December 29, 2011Applicants: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, LES HOSPICES CIVILS DE LYON, UNIVERSITE CLAUDE BERNARD DE LYON 1Inventors: Manuel Melchior Jean-Pierre Rosa Calatrava, Olivier Terrier, Francois Edouard Julien Durupt
-
Patent number: 8071550Abstract: A method for treating uterine disorders, including hyperplasic, hypertonic, cystic and/or neoplastic uterine gland tissue by local administration of a botulinum toxin to or to the vicinity of the afflicted uterine tissue.Type: GrantFiled: March 3, 2003Date of Patent: December 6, 2011Assignee: Allergan, Inc.Inventor: Rhett M. Schiffman
-
Publication number: 20110294739Abstract: The present invention relates to the use of an Engrailed transcription factor for producing a medicament for anxiolytic purposes.Type: ApplicationFiled: February 28, 2007Publication date: December 1, 2011Inventors: Alain Prochiantz, Michel Volovitch
-
Patent number: 8066997Abstract: The present invention relates to methods for modulating the activity of one or more neurotrophins, such as neural growth factor (NGF), brain derived neurotrophic factor (BDNF), neurotrophin-3, and neurotrophin-4 (NT-4), in an animal and methods for treatment of a disease or disorder in an individual by modulation of neurotrophin activity. The modulation is carried out by interfering with binding between a neurotrophin and a receptor of the Vps10p-domain receptor family or modulating the expression of a receptor of the Vps10p-domain receptor family. Methods for screening for agents capable of modulating neurotrophin activity and agents selected using these screening methods are also disclosed, as are methods for determining the effect of an agent on one or more neurotrophins in cells. The present invention also pertains to methods for modulating the transport of one or more neurotrophins.Type: GrantFiled: December 19, 2003Date of Patent: November 29, 2011Inventors: Anders Nykjaer, Claus Munck Petersen
-
Patent number: 8058243Abstract: A clonogenic neurosphere assay is described that carries out high throughput screens (HTS) to identify potent and/or selective modulators of proliferation, differentiation and/or renewal of neural precursor cells, neural progenitor cells and/or self-renewing and multipotent neural stem cells (NSCs). Compositions comprising the identified modulators and methods of using the modulators and compositions, in particular to treat neurological disorders (e.g. brain or CNS cancer) or damage are also disclosed.Type: GrantFiled: October 12, 2007Date of Patent: November 15, 2011Assignees: HSC Research and Development Limited Partnership, Mount Sinai HospitalInventors: Mike Tyers, Phedias Diamandis, Peter B. Dirks
-
Patent number: 8048858Abstract: A peptide consisting of 5 to 30 amino acid residues, preferably 9 to 15, most preferably about 12 amino acid residues, comprising a B epitope of a poly-?2,8 sialic acid attached to NCAM which is recognized by an anti-poly-?2,8 sialic acid (PSA) antibody, the use thereof and the preparation of a medicament for modulating NCAM functions, to be administered for the prevention and/or the treatment of neurodegenerative diseases, brain and spine lesions, age-related learning and memory problems, and cancer is disclosed.Type: GrantFiled: July 18, 2008Date of Patent: November 1, 2011Assignees: Centre National de la Recherche Scientifique, Universite de la Mediterranee Aix-Marseilles 2, Schafer-N, Universitaetsklinikum Hamburg-EppendorfInventors: Genevieve Rougon, Pascal Torregrossa, Melitta Schachner, Claus Schafer Nielsen
-
Patent number: 8034778Abstract: The present invention relates to a neuroprotective compound consisting of the amino acid sequence DLHW.Type: GrantFiled: May 3, 2007Date of Patent: October 11, 2011Assignee: Ever Neuro Pharma GmbHInventors: Monika Hitzl, Herbert Mossler, Heinz Schnait
-
Publication number: 20110224147Abstract: A method for inducing an analgesic response to inflammatory or neuropathic pain by administration of 1-(2-(4-chlorophenyl)-2-hydroxy)ethyl-4-(3,5-bis(1,1 dimethyl)-4-hydroxyphenyl)methyl piperazine, also called CNSB002 or AM-36, either alone or with an opioid and/or a neurokinin (NK) antagonist.Type: ApplicationFiled: July 31, 2009Publication date: September 15, 2011Applicant: Relevare Aust. Pyt. Ltd.Inventor: Colin Stanley Goodchild
-
Patent number: 8008253Abstract: The invention provides methods of treating or effecting prophylaxis of a patient having or at risk of developing symptoms of anxiety in which an effective regime of an agent that inhibits specific binding of PSD95 to an NMDA receptor is administered to a patient.Type: GrantFiled: July 1, 2008Date of Patent: August 30, 2011Inventors: Andrew Tasker, Tracy Doucette, Michael Tymianski, Kenneth Mendoza, Michael P. Belmares, David Garman, Peter S. Lu
-
Patent number: 7994123Abstract: Polypeptides of the neuregulin (NRG) heparin binding domain (N-HBD) and nucleic acids coding therefor are disclosed. In particular, fusion polypeptides are produced that comprise, as a targeting structure, a N-HBD polypeptide, fragment, homologue or functional derivative and a protein to be targeted. This is fused to a polypeptide or peptide being targeted (P<SUB>trg</SUB>) to cell surfaces rich in heparan sulfate proteoglycans to either activate or inhibit interactions at tyrosine kinase receptors. A preferred fusion polypeptide comprises an N-HBD, a spacer and the extracellular domain of erbB4, one of several receptors signaled by NRG, which is potent NRG antagonist. Such products are used to treat diseases or conditions where either agonism or antagonism at tyrosine kinase receptors has beneficial effects, including cancer and a multitude of diseases of the nervous system.Type: GrantFiled: July 8, 2005Date of Patent: August 9, 2011Assignee: Wayne State UniversityInventor: Jeffrey A. Loeb
-
Publication number: 20110178025Abstract: The present invention relates to novel proteins, referred to herein as amidated glial cell line-derived neurotrophic factor (GDNF) peptides (or “Amidated Dopamine Neuron Stimulating peptides (ADNS peptides)”), that are useful for treating brain diseases and injuries that result in dopaminergic deficiencies.Type: ApplicationFiled: December 23, 2009Publication date: July 21, 2011Applicant: University of Kentucky Research FoundationInventors: Luke H. Bradley, Don M. Gash, Greg A. Gerhardt, John D. Glass
-
Publication number: 20110091467Abstract: The present invention provides for diagnosis or treatment of neurological or neuropsychiatric disorders involving abnormal dopamine neurotransmission. Methods and agents are provided for modulating dopamine transporter activity and modulating dopaminergic neurotransmission. Agents of the present invention include fragments of D2 receptor or dopamine transporter (DAT) that can disrupt D2-DAT coupling.Type: ApplicationFiled: October 14, 2010Publication date: April 21, 2011Inventor: FANG LIU
-
Publication number: 20110053859Abstract: The invention provides methods of treating symptoms of sleep deprivation using a hypocretin agonist. The invention also provides methods of treating Parkinson's disease using a hypocretin agonist.Type: ApplicationFiled: October 10, 2008Publication date: March 3, 2011Applicant: The U. S. Government Respresented by the Department of Veterans AffairsInventors: Samuel A. Deadwyler, Robert E. Hampson, Linda Porrino, Michael Todd, Thomas N. Thannickal, Yuan-Yan Lai, Jerome M. Siegel
-
Patent number: 7884077Abstract: The invention features methods of treating mood disorders, such as manic disorders, and stabilizing moods by administering a kappa agonist or partial agonist to a subject in need thereof.Type: GrantFiled: August 27, 2008Date of Patent: February 8, 2011Assignee: The McLean Hospital CorporationInventors: Bruce M. Cohen, Beth L. Murphy
-
Patent number: 7846897Abstract: A method of inhibiting the binding between N-methyl-D-aspartate receptors and neuronal proteins in a neuron the method comprising administering to the neuron an effective inhibiting amount of a peptide replacement agent for the NMDA receptor or neuronal protein interaction domain that effect said inhibition of the NMDA receptor neuronal protein. The method is of value in reducing the damaging effect of injury to mammalian cells. Postsynaptic density-95 protein (PSD-95) couples neuronal N-methyl-D-aspartate receptors (NMDARs) to pathways mediating excitotoxicity and ischemic brain damage. This coupling was disrupted by transducing neurons with peptides that bind to modular domains on either side of the PSD-95/NMDAR interaction complex. This treatment attenuated downstream NMDAR signaling without blocking NMDAR activity, protected cultured cortical neurons from excitotoxic insults and dramatically reduced cerebral infarction volume in rats subjected to transient focal cerebral ischemia.Type: GrantFiled: August 20, 2007Date of Patent: December 7, 2010Inventor: Michael Tymianski
-
Publication number: 20100292149Abstract: The invention provides a method for treating amyotrophic lateral sclerosis (ALS) in a subject. The method comprises administering to the nervous system of the subject a composition comprising a thyroxine protein or a therapeutic fragment or pharmacologic mimic thereof and a pharmaceutically acceptable carrier. The invention also provides a method for treating ALS in a subject that comprises administering to the subject a transthyretin protein, 7B2 protein, a cystatin C protein, a neuroendocrine protein, a cysteine protease inhibitor, or an inhibitor of an enzyme that processes a 7B2 protein. In addition, the invention provides methods for determining the susceptibility of a subject to developing ALS and for determining the progression of ALS in a subject.Type: ApplicationFiled: July 24, 2009Publication date: November 18, 2010Inventor: Robert P. Bowser
-
Publication number: 20100249372Abstract: The present invention is based on the identification of synaptic vessel glycoprotein SV2 as the BoNT/A receptor and the further identification of various BoNT/A-binding fragments of SV2. The disclosure here provides new tools for diagnosing and treating botulism.Type: ApplicationFiled: October 12, 2006Publication date: September 30, 2010Inventors: Edwin R. Chapman, Min Dong